ResearcherWashington University in St. LouisActive in the last 2 years
C. Alston James
Matched on ORCID iD 0000-0003-4978-5198; OpenAlex author ID A5081343349. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 1 paper
Papers 5
- Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2024.2320411↗
- Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
- Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
- Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-21-0946↗
- Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-21-0998↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- William G. Hawkins · 5 shared papers, 2021–2024 · strength 0.74
- Paper Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenoc… DOI 10.1080/2162402x.2024.2320411↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- David G DeNardo · 5 shared papers, 2021–2024 · strength 0.74
- Paper Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenoc… DOI 10.1080/2162402x.2024.2320411↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Graham D. Hogg · 4 shared papers, 2021–2024 · strength 0.60
- Paper Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenoc… DOI 10.1080/2162402x.2024.2320411↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Ryan C Fields · 4 shared papers, 2021–2024 · strength 0.60
- Paper Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenoc… DOI 10.1080/2162402x.2024.2320411↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- John M. Baer · 3 shared papers, 2023 · strength 0.43
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Usman Younis Panni · 2 shared papers, 2023 · strength 0.29
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Varintra E. Lander · 2 shared papers, 2023 · strength 0.29
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Kian‐Huat Lim · 2 shared papers, 2023 · strength 0.28
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- William E. Gillanders · 2 shared papers, 2021–2023 · strength 0.26
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998↗
- Chong Zuo · 2 shared papers, 2021–2023 · strength 0.25
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Paper Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients w… DOI 10.1158/1078-0432.ccr-21-0998↗
- Yongwoo David Seo · 1 shared paper, 2024 · strength 0.20
- Venu Gopal Pillarisetty · 1 shared paper, 2024 · strength 0.20
- Vikram S. Pothuri · 1 shared paper, 2024 · strength 0.20
- Liang‐I Kang · 1 shared paper, 2023 · strength 0.15
- Feng Gao · 1 shared paper, 2023 · strength 0.14
- Daoxiang Zhang · 1 shared paper, 2023 · strength 0.14
- Jad I. Belle · 1 shared paper, 2023 · strength 0.14
- Paarth B. Dodhiawala · 1 shared paper, 2023 · strength 0.14
- Daniel Cui Zhou · 1 shared paper, 2023 · strength 0.14
- Li Ding · 1 shared paper, 2023 · strength 0.14
- Katharine E. Caldwell · 1 shared paper, 2021 · strength 0.11
- Hui Chin Peng · 1 shared paper, 2021 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.